Trial | NCT00530881  Report issue

Title

Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    180
This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2 diabetes ) or placebo. The drug is a "DPP4 inhibitor"
Study Started
Apr 30
2006
Study Completion
Oct 31
2006
Last Update
Sep 18
2007
Estimate

Drug PHX1149

4 Placebo Comparator

3 active, 1 placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Type 2 diabetes mellitus treatment with metformin +/- TZD

Exclusion Criteria:

Type 1 diabetes mellitus
No Results Posted